Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Price, News & Analysis

Chinook Therapeutics logo

About Chinook Therapeutics Stock (NASDAQ:KDNY)

Key Stats

Today's Range
$40.39
$40.39
50-Day Range
$38.66
$40.39
52-Week Range
$18.34
$40.51
Volume
N/A
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KDNY Stock News Headlines

Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Chinook Elementary
Chinook Therapeutics, Inc. (KDNY)
Expert Ratings for Chinook Therapeutics
See More Headlines

KDNY Stock Analysis - Frequently Asked Questions

Chinook Therapeutics, Inc. (NASDAQ:KDNY) released its earnings results on Tuesday, May, 9th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.03. Chinook Therapeutics's revenue was down 32.2% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chinook Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NIO (NIO), Ovintiv (OVV), Plug Power (PLUG), AMC Entertainment (AMC) and Applied Materials (AMAT).

Company Calendar

Last Earnings
5/09/2023
Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KDNY
Fax
N/A
Employees
214
Year Founded
N/A

Profitability

Net Income
$-187,870,000.00
Net Margins
-4,199.93%
Pretax Margin
-4,115.56%

Debt

Sales & Book Value

Annual Sales
$6.13 million
Book Value
$6.91 per share

Miscellaneous

Free Float
59,749,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.34
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:KDNY) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners